Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD

Blood (2011) 118 (21): 3718.

https://doi.org/10.1182/blood.V118.21.3718.3718

Published: 2011

Journal Articles

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Jaymie Estrella, PhD, Sattva S. Neelapu, MD, Richard Eric Davis, MD, Laurence Doyle, MD, Richard F Little, MD, MPH, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 3729.

https://doi.org/10.1182/blood.V118.21.3729.3729

Published: 2011

Journal Articles

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Sattva S. Neelapu, MD, Francisco Vega, MD, PhD, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 4965.

https://doi.org/10.1182/blood.V118.21.4965.4965

Published: 2011

Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD

Blood (2010) 116 (21): 3964.

https://doi.org/10.1182/blood.V116.21.3964.3964

Published: 2010

Journal Articles

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Anas Younes, MD, Francisco Hernandez, R. Gregory Bociek, MD, Yvette L. Kasamon, Peter Lee, MD, PhD, Lia Gore, MD, Daniela Buglio, MD, PhD, Amanda Copeland

Blood (2010) 116 (21): 3959.

https://doi.org/10.1182/blood.V116.21.3959.3959

Published: 2010

Journal Articles

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

Enrico Derenzini, MD, Daniela Buglio, MD, PhD, Hiroshi Katayama, PhD, Yuan Ji, PhD, Subrata Sen, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2848.

https://doi.org/10.1182/blood.V116.21.2848.2848

Published: 2010

Journal Articles

The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

Adam Jona, Noor Khaskhely, MD, PhD, Daniela Buglio, MD, PhD, Jessica A. Shafer, MD, Enrico Derenzini, MD, Catherine M Bollard, MD, Arpad Illes, MD, PhD, Michael Andreef, MD, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2850.

https://doi.org/10.1182/blood.V116.21.2850.2850

Published: 2010

Journal Articles

The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

Manuela Lemoine, PhD, Daniela Buglio, MD, PhD, Adam Jona, Enrico Derenzini, MD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2851.

https://doi.org/10.1182/blood.V116.21.2851.2851

Published: 2010

Journal Articles

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Daniela Buglio, MD, PhD, Sangeetha Palakurti, PhD, Francisco Vega, PhD, Sattva S. Neelapu, Donald Berry, PhD, Yuan Ji, PhD, Kate Byth, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2852.

https://doi.org/10.1182/blood.V116.21.2852.2852

Published: 2010

Journal Articles

The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction.

Noor M Khaskhely, MD, PhD, Daniela Buglio, MD, Jessica Shafer, MD, Catherine M. Bollard, MD, FRACP, FRCPA, Anas Younes, MD

Blood (2009) 114 (22): 1562.

https://doi.org/10.1182/blood.V114.22.1562.1562

Published: 2009

Journal Articles

The Tak-1 Inhibitor AZ-Tak1 Inhibits XIAP, Activates Caspase-9, and Induces Apoptosis in Mantle Cell Lymphoma.

Daniela Buglio, MD, Sangeetha Palakurthi, Senior, Scientist, Katharine F. Byth, Anas Younes, MD

Blood (2009) 114 (22): 1692.

https://doi.org/10.1182/blood.V114.22.1692.1692

Published: 2009

Journal Articles

The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma.

Daniela Buglio, MD, Vidya Mamidipudi, Noor M Khaskhely, MD, PhD, Annunziata Gloghini, Antonino Carbone, MD, Carla Heise, Jeffrey M. Besterman, PhD, BSc, Robert E Martell, Kyle J MacBeth, Anas Younes, MD

Blood (2009) 114 (22): 3735.

https://doi.org/10.1182/blood.V114.22.3735.3735

Published: 2009

Journal Articles

Differential Effect of the Histone Deacetylase Inhibitors Vorinostat and MGCD0103 in Cell-Free and Cell-Based Assays

Daniela Buglio, MD, Noor M Khaskhely, MD, PhD, George V Georgakis, MD, Anas Younes, MD

Blood (2008) 112 (11): 4827.

https://doi.org/10.1182/blood.V112.11.4827.4827

Published: 2008

Journal Articles

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Anas Younes, MD, Barbara Pro, MD, Michelle Fanale, MD, Peter McLaughlin, MD, Sattva Neelapu, MD, Luis Fayad, MD, Amanda Wedgwood, RN, APN, Daniela Buglio, MD, Tracy Patterson, RN, Marja Dubay, BSc., Zuomei Li, Ph.D., Robert E. Martell, MD, Ph.D., M. Renee Ward, MD, Ph.D., R. Gregory Bociek, MD, MSc., FRCPC

Blood (2007) 110 (11): 2566.

https://doi.org/10.1182/blood.V110.11.2566.2566

Published: 2007

Journal Articles

Vorinostat (SAHA) Inhibits STAT6 Phosphorylation and Transcription, Downregulates Bcl-xL, and Induces Apoptosis in Hodgkin Lymphoma (HL) Cell Lines.

Daniela Buglio, MD, Georgios Georgakis, M.D., Kazuhiko Arima, Ph.D., Yong-Jun Liu, Ph.D., Anas Younes, M.D.

Blood (2007) 110 (11): 380.

https://doi.org/10.1182/blood.V110.11.380.380

Published: 2007

Journal Articles

Hypoxia Induces Imatinib Resistance in CML Cell Lines.

Daniela Buglio, MD, Piera La Cava, MSc, Fabio Stagno, MD, Annalisa Chiarenza, MD, Salvatore Berretta, MD, Alesandra Aloisi, MSc, Giuseppe A. Palumbo, MD, Paolo Vigneri, MD, Francesco Di Raimondo, MD

Blood (2006) 108 (11): 4387.

https://doi.org/10.1182/blood.V108.11.4387.4387

Published: 2006

Journal Articles

In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.

Salvatore Berretta, MD, Annalisa Chiarenza, MD, Luana Adamo, MS, Laura Parrinello, MS, Daniela Buglio, MD, Fabio Stagno, MD, Daniele Tibullo, MS, Concetta Conticello, MD, PhD, Giuseppe A. Palumbo, MD, PhD, Francesco Di Raimondo, MD

Blood (2006) 108 (11): 4981.

https://doi.org/10.1182/blood.V108.11.4981.4981

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction.

The Tak-1 Inhibitor AZ-Tak1 Inhibits XIAP, Activates Caspase-9, and Induces Apoptosis in Mantle Cell Lymphoma.

The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma.

Differential Effect of the Histone Deacetylase Inhibitors Vorinostat and MGCD0103 in Cell-Free and Cell-Based Assays

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Vorinostat (SAHA) Inhibits STAT6 Phosphorylation and Transcription, Downregulates Bcl-xL, and Induces Apoptosis in Hodgkin Lymphoma (HL) Cell Lines.

Hypoxia Induces Imatinib Resistance in CML Cell Lines.

In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only